Patient Recovery from COVID-19 Infections: Follow-Up of Hair, Nail, and Cutaneous Manifestations

Table 2

Cutaneous manifestations in COVID-19 patients.

Cutaneous manifestations	Onset of rashes	Number of patients	Duration from date of COVID-19 diagnosis (days)	Severity of COVID-19	Medications during onset of skin manifestation	Duration of rashes	Treatment
Relevant manifestations
Urticaria	Before admission	1	3	Mild	No	1 day	No
	After discharge	1	150 (after discharge 120 days)	Critical	No	7 days	No
Maculopapular rash	During admission	1	2	Moderate	(i) Lpv/r 400/200 mg/d (day 3); (ii) CQ 500 mg/d (day 3)	2 weeks	(i) Desoximetasone cream; (ii) Cetirizine; (iii) Loratadine
		1	10	Severe	(i) Lpv/r 400/200 mg/d (5 days); (ii) CQ 500 mg/d (5 days); (iii) DRV 1,200 mg/d (day 5); (iv) RTV 200 mg/d (day 5); (v) HCQ 1,000 mg/d (day 5); (vi) FVR 1,200 mg/d (day 7)	5 days	(i) 0.1% triamcinolone cream
	After discharge	1	12 (after discharge 7 days)	Mild	No	3 days	No
Possibly relevant manifestations
Petechiae	During admission	1	2	Mild	No	2 days	No
Eczema	During admission	1	2	Mild	No	2 days	No
Other manifestations
Aggravation of psoriasis (plaque type)	After discharge	1	23 (after discharge 10 days)	Severe	No	2 weeks	(i) triamcinolone cream; (ii); (iii) 0.02% triamcinolone cream; (iv) Tar shampoo

CQ: chloroquine; DRV: darunavir; FVR: favipiravir; HCQ: hydroxychloroquine; Lpv/r: lopinavir/ritonavir; RTV: ritonavir.